Molecular and cellular aspects of protein misfolding and disease

FASEB Journal

Volumn 22, Issue 7, 2008, Pages 2115-2133

  Herczenik, Eszter ^a   Gebbink, Martijn F B G ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Crossbeta Biosciences BV   (Netherlands)

Author keywords

Aggregation; Alzheimer's disease; Amyloid; Atherosclerosis; Protein structure; Therapy

Indexed keywords

AL 108; AMYLIN ANTIBODY; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; ANTIDIABETIC AGENT; ATG Z1; AZD 103; BAPINEUZUMAB; BI 204; CAD 106; CARDIOVASCULAR AGENT; HOMOTAURINE; INSULIN; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NEUROPROTECTIVE AGENT; NOX A42; PAZ 417; PF 4494700; PRION PROTEIN; PROTEIN ANTIBODY; SERUM AMYLOID A; TAU PROTEIN; TTP 4000;

ALPHA HELIX; ALZHEIMER DISEASE; AMYLOIDOSIS; ATHEROSCLEROSIS; BETA SHEET; DRUG TARGETING; ENVIRONMENTAL CHANGE; GLYCATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE ACTIVATION; VASCULITIS;

BLOOD PROTEINS; DISEASE; ENZYMES; HUMANS; MODELS, MOLECULAR; PLATELET ACTIVATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEINS; VASCULAR DISEASES;

EID: 46749117136     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-099671     Document Type: Review

References (281)

1. Bryngelson, J. D., Onuchic, J. N., Socci, N. D., and Wolynes, P. G. (1995) Funnels, pathways, and the energy landscape of protein folding: a synthesis. Proteins 21, 167-195
2. Jahn, T. R., and Radford, S. E. (2005) The yin and yang of protein folding. FEBS J. 272, 5962-5970
3. Leopold, P. E., Montal, M., and Onuchic, J. N. (1992) Protein folding funnels: a kinetic approach to the sequence-structure relationship. Proc. Natl. Acad. Sci. U. S. A. 89, 8721-8725
4. Doyle, R., Simons, K., Qian, H., and Baker, D. (1997) Local interactions and the optimization of protein folding. Proteins 29, 282-291
5. Lindorff-Larsen, K., Rogen, P., Paci, E., Vendruscolo, M., and Dobson, C. M. (2005) Protein folding and the organization of the protein topology universe. Trends Biochem. Sci. 30, 13-19
6. Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen, A. O., Riekel, C., Grothe, R., and Eisenberg, D. (2005) Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773-778
7. Linding, R., Schymkowitz, J., Rousseau, F., Diella, F., and Serrano, L. (2004) A comparative study of the relationship between protein structure and β-aggregation in globular and intrinsically disordered proteins. J. Mol. Biol. 342, 345-353
8. Stix, B., Kahne, T., Sletten, K., Raynes, J., Roessner, A., and Rocken, C. (2001) Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am. J. Pathol. 159, 561-570
9. Horwich, A. L., and Weissman, J. S. (1997) Deadly conformations - protein misfolding in prion disease. Cell 89, 499-510
10. Laidman, J., Forse, G. J., and Yeates, T. O. (2006) Conformational change and assembly through edge β strands in transthyretin and other amyloid proteins. Acc. Chem. Res. 39, 576-583
11. Buxbaum, J. N. (2004) The systemic amyloidoses. Curr. Opin. Rheumatol. 16, 67-75
12. Rousseau, F., Schymkowitz, J., and Serrano, L. (2006) Protein aggregation and amyloidosis: confusion of the kinds? Curr. Opin. Struct. Biol. 16, 118-126
13. Huang, T. H., Yang, D. S., Fraser, P. E., and Chakrabartty, A. (2000) Alternate aggregation pathways of the Alzheimer β-amyloid peptide: an in vitro model of preamyloid. J. Biol. Chem. 275, 36436-36440
14. Wetzel, R. (2006) Kinetics and thermodynamics of amyloid fibril assembly. Acc. Chem. Res. 39, 671-679
15. Suzuki, E., Crewther, W. G., Fraser, R. D., MacRae, T. P., and McKern, N. M. (1973) X-ray diffraction and infrared studies of an α-helical fragment from α-keratin. J. Mol. Biol. 73, 275-278
16. Wilcock, D. M., Gordon, M. N., and Morgan, D. (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat. Protoc. 1, 1591-1595
17. LeVine, H., III (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410
18. Meredith, S. C. (2005) Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann. N. Y. Acad. Sci. 1066, 181-221
19. Astbury, W. T., and Dickinson, S. (1935) The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem. J. 29, 2351-2360
20. Rudall, K. M. (1952) The proteins of the mammalian epidermis. Adv. Protein Chem. 7, 253-290
21. Jenkins, J., and Pickersgill, R. (2001) The architecture of parallel βa-helices and related folds. Prog. Biophys. Mol. Biol. 77, 111-175
22. Chan, J. C., Oyler, N. A., Yau, W. M., and Tycko, R. (2005) Parallel β-sheets and polar zippers in amyloid fibrils formed by residues 10-39 of the yeast prion protein Ure2p. Biochemistry 44, 10669-10680
23. Roher, A. E., Baudry, J., Chaney, M. O., Kuo, Y. M., Stine, W. B., and Emmerling, M. R. (2000) Oligomerizaiton and fibril assembly of the amyloid-β protein. Biochim. Biophys. Acta 1502, 31-43
24. Chaney, M. O., Webster, S. D., Kuo, Y. M., and Roher, A. E. (1998) Molecular modeling of the Aβ1-42 peptide from Alzheimer's disease. Protein Eng. 11, 761-767
25. Eisenberg, D., Nelson, R., Sawaya, M. R., Balbirnie, M., Sambashivan, S., Ivanova, M. I., Madsen, A. O., and Riekel, C. (2006) The structural biology of protein aggregation diseases: fundamental questions and some answers. Acc. Chem. Res. 39, 568-575
26. Sawaya, M. R., Sambashivan, S., Nelson, R., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzius, J. J., McFarlane, H. T., Madsen, A. O., Riekel, C., and Eisenberg, D. (2007) Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447, 453-457
27. Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., and Giasson, B. I. (2005) The E46K mutation in α-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800-7807
28. Tsubuki, S., Takaki, Y., and Saido, T. C. (2003) Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation. Lancet 361, 1957-1958
29. Azuaga, A. I., Dobson, C. M., Mateo, P. L., and Conejero-Lara, F. (2002) Unfolding and aggregation during the thermal denaturation of streptokinase. Eur. J. Biochem. 269, 4121-4133
30. Iametti, S., De, G. B., Vecchio, G., and Bonomi, F. (1996) Modifications occur at different structural levels during the heat denaturation of β-lactoglobulin. Eur. J. Biochem. 237, 106-112
31. Giri, K., Bhattacharyya, N. P., and Basak, S. (2007) pH-dependent self-assembly of polyalanine peptides. Biophys. J. 92, 293-302
32. Vetri, V., Canale, C., Relini, A., Librizzi, F., Militello, V., Gliozzi, A., and Leone, M. (2007) Amyloid fibrils formation and amorphous aggregation in concanavalin A. Biophys. Chem. 125, 184-190
33. Fan, H., Vitharana, S. N., Chen, T., O'Keefe, D., and Middaugh, C. R. (2007) Effects of pH and polyanions on the thermal stability of fibroblast growth factor 20. Mol. Pharmacol. 4, 232-240
34. Carneiro, F. A., Ferradosa, A. S., and Da Poian, A. T. (2001) Low pH-induced conformational changes in vesicular stomatitis virus glycoprotein involve dramatic structure reorganization. J. Biol. Chem. 276, 62-67
35. De Felice, F. G., Vieira, M. N., Meirelles, M. N., Morozova-Roche, L. A., Dobson, C. M., and Ferreira, S. T. (2004) Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. FASEB J. 18, 1099-1101
36. Jansen, R., Grudzielanek, S., Dzwolak, W., and Winter, R. (2004) High pressure promotes circularly shaped insulin amyloid. J. Mol. Biol. 338, 203-206
37. Hill, E. K., Krebs, B., Goodall, D. G., Howlett, G. J., and Dunstan, D. E. (2006) Shear flow induces amyloid fibril formation. Biomacromolecules 7, 10-13
38. Mantyh, P. W., Ghilardi, J. R., Rogers, S., DeMaster, E., Allen, C. J., Stimson, E. R., and Maggio, J. E. (1993) Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J. Neurochem. 61, 1171-1174
39. Raghuraman, H., and Chattopadhyay, A. (2006) Effect of ionic strength on folding and aggregation of the hemolytic peptide melittin in solution. Biopolymers 83, 111-121
40. Ohhashi, Y., Kihara, M., Naiki, H., and Goto, Y. (2005) Ultrasonication-induced amyloid fibril formation of β2-microglobulin. J. Biol. Chem. 280, 32843-32848
41. De Jong, K. L., Incledon, B., Yip, C. M., and DeFelippis, M. R. (2006) Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy. Biophys. J. 91, 1905-1914
42. Zhu, M., Souillac, P. O., Ionescu-Zanetti, C., Carter, S. A., and Fink, A. L. (2002) Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 277, 50914-50922
43. Schladitz, C., Vieira, E. P., Hermel, H., and Mohwald, H. (1999) Amyloid-β-sheet formation at the air-water interface. Biophys. J. 77, 3305-3310
44. Kudryashova, E. V., Meinders, M. B., Visser, A. J., van Hoek, A., and de Jongh, H. H. (2003) Structure and dynamics of egg white ovalbumin adsorbed at the air/water interface. Eur. Biophys. J. 32, 553-562
45. Zhao, H., Tuominen, E. K., and Kinnunen, P. K. (2004) Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43, 10302-10307
46. Zhao, H., Jutila, A., Nurminen, T., Wickstrom, S. A., Keski-Oja, J., and Kinnunen, P. K. (2005) Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. Biochemistry 44, 2857-2863
47. Schmitt, H. P. (2006) ε-Glycation, APP and Aβ in ageing and Alzheimer disease: a hypothesis. Med. Hypotheses 66, 898-906
48. Bouma, B., Kroon-Batenburg, L. M., Wu, Y. P., Brunjes, B., Posthuma, G., Kranenburg, O., de Groot, P. G., Voest, E. E., and Gebbink, M. F. (2003) Glycation induces formation of amyloid cross-β structure in albumin. J. Biol. Chem. 278, 41810-41819
49. Rakhit, R., Cunningham, P., Furtos-Matei, A., Dahan, S., Qi, X. F., Crow, J. P., Cashman, N. R., Kondejewski, L. H., and Chakrabartty, A. (2002) Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277, 47551-47556
50. Stewart, C. R., Tseng, A. A., Mok, Y. F., Staples, M. K., Schiesser, C. H., Lawrence, L. J., Varghese, J. N., Moore, K. J., and Howlett, G. J. (2005) Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry 44, 9108-9116
51. Stewart, C. R., Wilson, L. M., Zhang, Q., Pham, C. L., Waddington, L. J., Staples, M. K., Stapleton, D., Kelly, J. W., and Howlett, G. J. (2007) Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation. Biochemistry 46, 5552-5561
52. Merlini, G., and Bellotti, V. (2003) Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583-596
53. Gertz, M. A., and Rajkumar, S. V. (2002) Primary systemic amyloidosis. Curr. Treat. Options Oncol. 3, 261-271
54. Palladini, G., Perfetti, V., and Merlini, G. (2006) Therapy and management of systemic AL (primary) amyloidosis. Swiss Med. Wkly. 136, 715-720
55. Gertz, M. A., Lacy, M. Q., and Dispenzieri, A. (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 18, 17-37
56. Petersen, L. C., Bjorn, S. E., Norris, F., Norris, K., Sprecher, C., and Foster, D. C. (1994) Expression, purification and characterization of a Kunitz-type protease inhibitor domain from human amyloid precursor protein homolog. FEBS Lett. 338, 53-57
57. Caille, I., Allinquant, B., Dupont, E., Bouillot, C., Langer, A., Muller, U., and Prochiantz, A. (2004) Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131, 2173-2181
58. Schmitz, A., Tikkanen, R., Kirfel, G., and Herzog, V. (2002) The biological role of the Alzheimer amyloid precursor protein in epithelial cells. Histochem. Cell. Biol. 117, 171-180
59. Kirfel, G., Borm, B., Rigort, A., and Herzog, V. (2002) The secretory β-amyloid precursor protein is a mitogen for human epidermal keratinocytes. Eur. J. Cell. Biol. 81, 664-676
60. Grimm, M. O., Grimm, H. S., Patzold, A. J., Zinser, E. G., Halonen, R., Duering, M., Tschape, J. A., De, S. B., Muller, U., Shen, J., and Hartmann, T. (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat. Cell Biol. 7, 1118-1123
61. Hardy, J., and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
62. Golde, T. E., Dickson, D., and Hutton, M. (2006) Filling the gaps in the aβ cascade hypothesis of Alzheimer's disease. Curr. Alzheimer Res. 3, 421-430
63. Springer, T. A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314
64. Misra, A. (2000) Risk factors for atherosclerosis in young individuals. J. Cardiovasc. Risk 7, 215-229
65. Humphries, S. E., and Morgan, L. (2004) Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol. 3, 227-235
66. Rocken, C., Tautenhahn, J., Buhling, F., Sachwitz, D., Vockler, S., Goette, A., and Burger, T. (2006) Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler. Thromb. Vasc. Biol. 26, 676-677
67. Howlett, G. J., and Moore, K. J. (2006) Untangling the role of amyloid in atherosclerosis. Curr. Opin. Lipidol. 17, 541-547
68. Galle, J., Hansen-Hagge, T., Wanner, C., and Seibold, S. (2006) Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 185, 219-226
69. Husmann, M., and Barton, M. (2007) Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opin. Investig. Drugs 16, 563-567
70. Lahera, V., Goicoechea, M., de Vinuesa, S. G., Miana, M., de las Heras, N., Cachofeiro, V., and Luno, J. (2007) Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem. 14, 243-248
71. Famularo, G., Miele, L., Minisola, G., and Grieco, A. (2007) Liver toxicity of rosuvastatin therapy. World J. Gastroenterol. 13, 1286-1288
72. Tiwari, A., Bansal, V., Chugh, A., and Mookhtiar, K. (2006) Statins and myotoxicity: a therapeutic limitation. Expert Opin. Drug Saf. 5, 651-666
73. Belcher, P. R., Drake-Holland, A. J., and Noble, M. I. (2006) The antiplatelet drug target in atherosclerotic diseases. Cardiovasc. Hematol. Disord. Drug Targets 6, 43-55
74. Holmsen, H. (1989) Physiological functions of platelets. Ann. Med. 21, 23-30
75. Cohen, I. (1979) The contractile system of blood platelets and its function. Methods Achiev. Exp. Pathol. 9, 40-86
76. Jurk, K., and Kehrel, B. E. (2005) Platelets: physiology and biochemistry. Semin. Thromb. Hemost. 31, 381-392
77. Ciabattoni, G., Porreca, E., Di Febbo, C., Di Iorio, A., Paganelli, R., Bucciarelli, T., Pescara, L., Del Re, L., Giusti, C., Falco, A., Sau, A., Patrono, C., and Davi, G. (2007) Determinants of platelet activation in Alzheimer's disease. Neurobiol. Aging 28, 336-342
78. Herczenik, E., Bouma, B., Korporaal, S. J., Strangi, R., Zeng, Q., Gros, P., Van, E. M., Van Berkel, T. J., Gebbink, M. F., and Akkerman, J. W. (2007) Activation of human platelets by misfolded proteins. Arterioscler. Thromb. Vasc. Biol. 27, 1657-1665
79. Kowalska, M. A., and Badellino, K. (1994) β-Amyloid protein induces platelet aggregation and supports platelet adhesion. Biochem. Biophys. Res. Commun. 205, 1829-1835
80. Korporaal, S. J., Gorter, G., van Rijn, H. J., and Akkerman, J. W. (2005) Effect of oxidation on the platelet-activating properties of low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 25, 867-872
81. 2+ homeostasis in diabetes mellitus. Am. J. Physiol. 280, H1480-H1489
82. Hausfater, P., Costedoat-Chalumeau, N., Amoura, Z., Cacoub, P., Papo, T., Grateau, G., Leblond, V., Godeau, P., and Piette, J. C. (2005) AL cardiac amyloidosis and arterial thromboembolic events. Scand. J. Rheumatol. 34, 315-319
83. Halligan, C. S., Lacy, M. Q., Vincent, R. S., Dispenzieri, A., Witzig, T. E., Lust, J. A., Fonseca, R., Gertz, M. A., Kyle, R. A., and Pruthi, R. K. (2006) Natural history of thromboembolism in AL amyloidosis. Amyloid 13, 31-36
84. Skovronsky, D. M., Lee, V. M., and Pratico, D. (2001) Amyloid precursor protein and amyloid β peptide in human platelets: role of cyclooxygenase and protein kinase C. J. Biol. Chem. 276, 17036-17043
85. Matsubara, E., Shoji, M., Murakami, T., Abe, K., Frangione, B., and Ghiso, J. (2002) Platelet microparticles as carriers of soluble Alzheimer's amyloid β (sAβ). Ann. N. Y. Acad. Sci. 977, 340-348
86. Tan, K. T., Tayebjee, M. H., Lim, H. S., and Lip, G. Y. (2005) Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet. Med. 22, 1657-1662
87. Koga, H., Sugiyama, S., Kugiyama, K., Fukushima, H., Watanabe, K., Sakamoto, T., Yoshimura, M., Jinnouchi, H., and Ogawa, H. (2006) Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur. Heart J. 27, 817-823
88. Siddiqui, F. A., Desai, H., Amirkhosravi, A., Amaya, M., and Francis, J. L. (2002) The presence and release of tissue factor from human platelets. Platelets 13, 247-253
89. Davies, T. A., Long, H. J., Eisenhauer, P. B., Hastey, R., Cribbs, D. H., Fine, R. E., and Simons, E. R. (2000) β Amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. Amyloid 7, 153-165
90. Skoog, I., and Gustafson, D. (2006) Update on hypertension and Alzheimer's disease. Neurol. Res. 28, 605-611
91. Stohs, S. J. (1995) The role of free radicals in toxicity and disease. J. Basic Clin. Physiol. Pharmacol. 6, 205-228
92. Messier, C., and Gagnon, M. (1996) Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav. Brain Res. 75, 1-11
93. Suji, G., and Sivakami, S. (2004) Glucose, glycation and aging. Biogerontology 5, 365-373
94. Squier, T. C. (2001) Oxidative stress and protein aggregation during biological aging. Exp. Gerontol. 36, 1539-1550
95. Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van, H. F., van Duijn, C. N., Van, B. C., and Grobbee, D. E. (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349, 151-154
96. Casserly, I., and Topol, E. (2004) Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146
97. Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., and Bennett, D. A. (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661-666
98. Betsuyaku, T., Adachi, T., Haneda, H., Suzuki, J., Nishimura, M., Abe, S., Ito, T., Fujioka, Y., and Kawakami, Y. (1993) A secondary amyloidosis associated with systemic lupus erythematosus. Intern. Med. 32, 391-394
99. Eulitz, M., Weiss, D. T., and Solomon, A. (1990) Immunoglobulin heavy-chain-associated amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 87, 6542-6546
100. Obici, L., Perfetti, V., Palladini, G., Moratti, R., and Merlini, G. (2005) Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta 1753, 11-22
101. Ohashi, K. (2001) Pathogenesis of β2-microglobulin amyloidosis. Pathol. Int. 51, 1-10
102. Genschel, J., Haas, R., Propsting, M. J., and Schmidt, H. H. (1998) Apolipoprotein A-I induced amyloidosis. FEBS Lett. 430, 145-149
103. Hawkins, P. N. (2003) Hereditary systemic amyloidosis with renal involvement. J. Nephrol. 16, 443-448
104. Benson, M. D., Liepnieks, J. J., Yazaki, M., Yamashita, T., Hamidi, A. K., Guenther, B., and Kluve-Beckerman, B. (2001) A new human hereditary amyloidosis: the result of a stopcodon mutation in the apolipoprotein AII gene. Genomics 72, 272-277
105. Kiuru, S. (1998) Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 5, 55-66
106. Tan, S. Y., and Pepys, M. B. (1994) Amyloidosis. Histopathology 25, 403-414
107. Palsdottir, A., Snorradottir, A. O., and Thorsteinsson, L. (2006) Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol. 16, 55-59
108. Swift, B. (2002) Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet. Med. 19, 881-882
109. Hamidi, A. L., Liepnieks, J. J., Uemichi, T., Rebibou, J. M., Justrabo, E., Droz, D., Mousson, C., Chalopin, J. M., Benson, M. D., Delpech, M., and Grateau, G. (1997) Renal amyloidosis with a frame shift mutation in fibrinogen aα-chain gene producing a novel amyloid protein. Blood 90, 4799-4805
110. Coyne, J. D., and Kealy, W. F. (1993) Seminal vesicle amyloidosis: morphological, histochemical and immunohistochemical observations. Histopathology 22, 173-176
111. Linke, R. P., Joswig, R., Murphy, C. L., Wang, S., Zhou, H., Gross, U., Rocken, C., Westermark, P., Weiss, D. T., and Solomon, A. (2005) Senile seminal vesicle amyloid is derived from seminogelin I. J. Lab. Clin. Med. 145, 187-193
112. Klintworth, G. K., Valnickova, Z., Kielar, R. A., Baratz, K. H., Campbell, R. J., and Enghild, J. J. (1997) Familial subepithelial corneal amyloidosis - a lactoferrin-related amyloidosis. Invest. Ophthalmol. Vis. Sci. 38, 2756-2763
113. Meehan, S., Berry, Y., Luisi, B., Dobson, C. M., Carver, J. A., and MacPhee, C. E. (2004) Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. J. Biol. Chem. 279, 3413-3419
114. Khurana, R., Agarwal, A., Bajpai, V. K., Verma, N., Sharma, A. K., Gupta, R. P., and Madhusudan, K. P. (2004) Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology 145, 5465-5470
115. Glenner, G. G., and Wong, C. W. (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131-1135
116. Ruben, G. C., Ciardelli, T. L., Grundke-Iqbal, I., and Iqbal, K. (1997) Alzheimer disease hyperphosphorylated tau aggregates hydrophobically. Synapse 27, 208-229
117. Iwatsubo, T. (2003) Aggregation of α-synuclein in the pathogenesis of Parkinson's disease. J. Neurol. 250(Suppl. 3), III11-III14
118. Mukaetova-Ladinska, E. B., Hurt, J., Jakes, R., Xuereb, J., Honer, W. G., and Wischik, C. M. (2000) α-Synuclein inclusions in Alzheimer and Lewy body diseases. J. Neuropathol. Exp. Neurol. 59, 408-417
119. Hoffner, G., and Djian, P. (2002) Protein aggregation in Huntington's disease. Biochimie (Paris) 84, 273-278
120. Johnson, R. T., and Gibbs, C. J., Jr. (1998) Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N. Engl. J. Med. 339, 1994-2004
121. Hainfellner, J. A., and Budka, H. (1999) Disease associated prion protein may deposit in the peripheral nervous system in human transmissible spongiform encephalopathies. Acta Neuropathol. (Berl.) 98, 458-460
122. Gudmundsson, G., Hallgrimsson, J., Jonasson, T. A., and Bjarnason, O. (1972) Hereditary cerebral haemorrhage with amyloidosis. Brain 95, 387-404
123. Ghiso, J., Jensson, O., and Frangione, B. (1986) Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of α-trace basic protein (cystatin C). Proc. Natl. Acad. Sci. U. S. A. 83, 2974-2978
124. Bowling, A. C., Barkowski, E. E., Kenna-Yasek, D., Sapp, P., Horvitz, H. R., Beal, M. F., and Brown, R. H., Jr. (1995) Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. J. Neurochem. 64, 2366-2369
125. Holton, J. L., Ghiso, J., Lashley, T., Rostagno, A., Guerin, C. J., Gibb, G., Houlden, H., Ayling, H., Martinian, L., Anderton, B. H., Wood, N. W., Vidal, R., Plant, G., Frangione, B., and Revesz, T. (2001) Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am. J. Pathol. 158, 515-526
126. Holton, J. L., Lashley, T., Ghiso, J., Braendgaard, H., Vidal, R., Guerin, C. J., Gibb, G., Hanger, D. P., Rostagno, A., Anderton, B. H., Strand, C., Ayling, H., Plant, G., Frangione, B., Bojsen-Moller, M., and Revesz, T. (2002) Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-β. J. Neuropathol. Exp. Neurol. 61, 254-267
127. Hou, X., Aguilar, M. I., and Small, D. H. (2007) Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 274, 1637-1650
128. Graff-Radford, N. R., and Woodruff, B. K. (2007) Frontotemporal dementia. Semin. Neurol. 27, 48-57
129. Johnson, K. H., O'Brien, T. D., Betsholtz, C., and Westermark, P. (1989) Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N. Engl. J. Med. 321, 513-518
130. Ursini, F., Davies, K. J., Maiorino, M., Parasassi, T., and Sevanian, A. (2002) Atherosclerosis: another protein misfolding disease? Trends Mol. Med. 8, 370-374
131. Merlini, G., Bellotti, V., Andreola, A., Palladini, G., Obici, L., Casarini, S., and Perfetti, V. (2001) Protein aggregation. Clin. Chem. Lab. Med. 39, 1065-1075
132. Murayama, M. (1972) Thermal (or endothermic) aggregation of sickle cell hemoglobin (Hb S) during sickling. Adv. Exp. Med. Biol. 28, 243-251
133. Chiti, F., and Dobson, C. M. (2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366
134. Pike, C. J., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314
135. Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., Teplow, D. B., and Selkoe, D. J. (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884
136. Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B. A. (1998) Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 4, 827-831
137. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489
138. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., and Rogers, J. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862
139. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866
140. Gertz, H. J., Siegers, A., and Kuchinke, J. (1994) Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Res. 637, 339-341
141. Sousa, M. M., Cardoso, I., Fernandes, R., Guimaraes, A., and Saraiva, M. J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993-2000
142. Kourie, J. I., and Henry, C. L. (2002) Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin. Exp. Pharmacol. Physiol. 29, 741-753
143. Rao, R. V., and Bredesen, D. E. (2004) Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr. Opin. Cell Biol. 16, 653-662
144. Soreghan, B., Kosmoski, J., and Glabe, C. (1994) Surfactant properties of Alzheimer's Aβ peptides and the mechanism of amyloid aggregation. J. Biol. Chem. 269, 28551-28554
145. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291
146. Mirzabekov, T. A., Lin, M. C., and Kagan, B. L. (1996) Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271, 1988-1992
147. Lashuel, H. A. (2005) Membrane permeabilization: a common mechanism in protein-misfolding diseases. Sci. Aging Knowledge Environ. 2005, e28
148. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., and Glabe, C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17294-17300
149. Lindholm, D., Wootz, H., and Korhonen, L. (2006) ER stress and neurodegenerative diseases. Cell Death Differ. 13, 385-392
150. Zhu, X., Su, B., Wang, X., Smith, M. A., and Perry, G. (2007) Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 64, 2202-2210
151. Emerit, J., Edeas, M., and Bricaire, F. (2004) Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58, 39-46
152. Stefani, M., and Dobson, C. M. (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678-699
153. Morishima, Y., Gotoh, Y., Zieg, J., Barrett, T., Takano, H., Flavell, R., Davis, R. J., Shirasaki, Y., and Greenberg, M. E. (2001) β-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551-7560
154. Bucciantini, M., Rigacci, S., Berti, A., Pieri, L., Cecchi, C., Nosi, D., Formigli, L., Chiti, F., and Stefani, M. (2005) Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar aggregates. FASEB J. 19, 437-439
155. Beal, M. F. (2002) Oxidatively modified proteins in aging and disease. Free. Radic. Biol. Med. 32, 797-803
156. Zhou, Y., Wang, Q., Mark, E. B., and Chung, D. H. (2006) Oxidative stress-induced intestinal epithelial cell apoptosis is mediated by p38 MAPK. Biochem. Biophys. Res. Commun. 350, 860-865
157. Rattan, S. I. (2004) Mechanisms of hormesis through mild heat stress on human cells. Ann. N. Y. Acad. Sci. 1019, 554-558
158. Mitchell, M. D., Laird, R. E., Brown, R. D., and Long, C. S. (2007) IL-1β stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am. J. Physiol. 292, H1139-H1147
159. Finch, C. E., and Morgan, T. E. (2007) Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr. Alzheimer Res. 4, 185-189
160. Heneka, M. T., and O'Banion, M. K. (2007) Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184, 69-91
161. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421
162. Griffin, W. S., Sheng, J. G., Royston, M. C., Gentleman, S. M., McKenzie, J. E., Graham, D. I., Roberts, G. W., and Mrak, R. E. (1998) Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8, 65-72
163. Williams, M. D., and Nadler, J. L. (2007) Inflammatory mechanisms of diabetic complications. Curr. Diab. Rep. 7, 242-248
164. Aguzzi, A., and Heikenwalder, M. (2006) Pathogenesis of prion diseases: current status and future outlook. Nat. Rev. Microbiol. 4, 765-775
165. Manuelidis, L., Fritch, W., and Xi, Y. G. (1997) Evolution of a strain of CJD that induces BSE-like plaques. Science 277, 94-98
166. Liang, C. P., Han, S., Senokuchi, T., and Tall, A. R. (2007) The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. 100, 1546-1555
167. Fujiwara, N., and Kobayashi, K. (2005) Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 4, 281-286
168. Gordon, S. (2002) Pattern recognition receptors: doubling up for the innate immune response. Cell 111, 927-930
169. Kabelitz, D., and Medzhitov, R. (2007) Innate immunity - cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19, 1-3
170. Febbraio, M., Hajjar, D. P., and Silverstein, R. L. (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785-791
171. Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., and Nawroth, P. P. (2005) Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83, 876-886
172. Herz, J., and Strickland, D. K. (2001) LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108, 779-784
173. Deane, R., Wu, Z., and Zlokovic, B. V. (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631
174. Kranenburg, O., Bouma, B., Kroon-Batenburg, L. M., Reijerkerk, A., Wu, Y. P., Voest, E. E., and Gebbink, M. F. (2002) Tissue-type plasminogen activator is a multiligand cross-β structure receptor. Curr. Biol. 12, 1833-1839
175. Melchor, J. P., and Strickland, S. (2005) Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 93, 655-660
176. Kranenburg, O., Gent, Y. Y., Romijn, E. P., Voest, E. E., Heck, A. J., and Gebbink, M. F. (2005) Amyloid-β-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors. Neuroscience 131, 877-886
177. Tsirka, S. E., Rogove, A. D., and Strickland, S. (1996) Neuronal cell death and tPA. Nature 384, 123-124
178. Veerhuis, R., Boshuizen, R. S., and Familian, A. (2005) Amyloid associated proteins in Alzheimer's and prion disease. Curr. Drug Targets CNS Neurol. Disord. 4, 235-248
179. Ono, K., and Uchino, F. (1994) Formation of amyloid-like substance from β-2-microglobulin in vitro: role of serum amyloid P component: a preliminary study. Nephron 66, 404-407
180. Hazenberg, B. P., van Rijswijk, M. H., Piers, D. A., Lub-de Hooge, M. N., Vellenga, E., Haagsma, E. B., Hawkins, P. N., and Jager, P. L. (2006)
181. Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., and Tenner, A. J. (1996) Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138, 22-32
182. Hasegawa, M., Kawashima, S., Shikano, M., Kojima, K., Yanai, T., Hassegawa, H., Tomita, M., Murakami, K., Kawamura, N., and Katsumata, H. (1995) C1Q complexes with β-2-microglobulin and amyloid P-component in sera of patients with dialysis-associated amyloidosis. Nephron 69, 380-383
183. Jiang, H., Burdick, D., Glabe, C. G., Cotman, C. W., and Tenner, A. J. (1994) β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152, 5050-5059
184. Blanquet-Grossard, F., Thielens, N. M., Vendrely, C., Jamin, M., and Arlaud, G. J. (2005) Complement protein C1q recognizes a conformationally modified form of the prion protein. Biochemistry 44, 4349-4356
185. Stewart, E. M., Aquilina, J. A., Easterbrook-Smith, S. B., Murphy-Durland, D., Jacobsen, C., Moestrup, S., and Wilson, M. R. (2007) Effects of glycosylation on the structure and function of the extracellular chaperone clusterin. Biochemistry 46, 1412-1422
186. Kumita, J. R., Poon, S., Caddy, G. L., Hagan, C. L., Dumoulin, M., Yerbury, J. J., Stewart, E. M., Robinson, C. V., Wilson, M. R., and Dobson, C. M. (2007) The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J. Mol. Biol. 369, 157-167
187. Yerbury, J. J., Poon, S., Meehan, S., Thompson, B., Kumita, J. R., Dobson, C. M., and Wilson, M. R. (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21, 2312-2322
188. Lam, M. C., Tan, K. C., and Lam, K. S. (2004) Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis 177, 313-320
189. Duryee, M. J., Freeman, T. L., Willis, M. S., Hunter, C. D., Hamilton, B. C., III, Suzuki, H., Tuma, D. J., Klassen, L. W., and Thiele, G. M. (2005) Scavenger receptors on sinusoidal liver endothelial cells are involved in the uptake of aldehydemodified proteins. Mol. Pharmacol. 68, 1423-1430
190. Van Oosten, M., van Amersfoort, E. S., Van Berkel, T. J., and Kuiper, J. (2001) Scavenger receptor-like receptors for the binding of lipopolysaccharide and lipoteichoic acid to liver endothelial and Kupffer cells. J. Endotoxin Res. 7, 381-384
191. Haworth, R., Platt, N., Keshav, S., Hughes, D., Darley, E., Suzuki, H., Kurihara, Y., Kodama, T., and Gordon, S. (1997) The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J. Exp. Med. 186, 1431-1439
192. Thomas, C. A., Li, Y., Kodama, T., Suzuki, H., Silverstein, S. C., and El Khoury, J. (2000) Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J. Exp. Med. 191, 147-156
193. Platt, N., da Silva, R. P., and Gordon, S. (1999) Class A scavenger receptors and the phagocytosis of apoptotic cells. Immunol. Lett. 65, 15-19
194. Miyazaki, A., Nakayama, H., and Horiuchi, S. (2002) Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc. Med. 12, 258-262
195. Fukuhara-Takaki, K., Sakai, M., Sakamoto, Y., Takeya, M., and Horiuchi, S. (2005) Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J. Biol. Chem. 280, 3355-3364
196. Yang, G., Addai, J., Tian, W. H., Frolov, A., Wheeler, T. M., and Thompson, T. C. (2004) Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res. 64, 2076-2082
197. Kieffer, N., Nurden, A. T., Hasitz, M., Titeux, M., and Breton-Gorius, J. (1988) Identification of platelet membrane thrombospondin binding molecules using an anti-thrombospondin antibody. Biochim. Biophys. Acta 967, 408-415
198. Greenberg, M. E., Sun, M., Zhang, R., Febbraio, M., Silverstein, R., and Hazen, S. L. (2006) Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 203, 2613-2625
199. Baruch, D. I., Gormely, J. A., Ma, C., Howard, R. J., and Pasloske, B. L. (1996) Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 93, 3497-3502
200. + sickle reticulocytes to endothelial cells. Blood 80, 2634-2642
201. Rigotti, A., Acton, S. L., and Krieger, M. (1995) The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270, 16221-16224
202. Tserentsoodol, N., Gordiyenko, N. V., Pascual, I., Lee, J. W., Fliesler, S. J., and Rodriguez, I. R. (2006) Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis. 12, 1319-1333
203. Febbraio, M., and Silverstein, R. L. (2007) CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol. 39, 2012-2030
204. Thorne, R. F., Mhaidat, N. M., Ralston, K. J., and Burns, G. F. (2007) CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 581, 1227-1232
205. Okamura, D. M., Lopez-Guisa, J. M., Koelsch, K., Collins, S. J., and Eddy, A. A. (2007) Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am. J. Physiol. 293, F575-F585
206. Chen, M., Masaki, T., and Sawamura, T. (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol. Ther. 95, 89-100
207. Horiuchi, S., Sakamoto, Y., and Sakai, M. (2003) Scavenger receptors for oxidized and glycated proteins. Amino Acids 25, 283-292
208. Duerrschmidt, N., Zabirnyk, O., Nowicki, M., Ricken, A., Hmeidan, F. A., Blumenauer, V., Borlak, J., and Spanel-Borowski, K. (2006) Lectin-like oxidized low-density lipoprotein receptor-1-mediated autophagy in human granulosa cells as an alternative of programmed cell death. Endocrinology 147, 3851-3860
209. Kakutani, M., Masaki, T., and Sawamura, T. (2000) A platele-tendothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc. Natl. Acad. Sci. U. S. A. 97, 360-364
210. Shimaoka, T., Kume, N., Minami, M., Hayashida, K., Sawamura, T., Kita, T., and Yonehara, S. (2001) LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J. Immunol. 166, 5108-5114
211. Ishino, S., Mukai, T., Kume, N., Asano, D., Ogawa, M., Kuge, Y., Minami, M., Kita, T., Shiomi, M., and Saji, H. (2007) Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability-analysis in hypercholesterolemic rabbits. Atherosclerosis 195, 48-56
212. Schmidt, A. M., and Stern, D. (2000) Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep. 2, 430-436
213. Sparatore, B., Pedrazzi, M., Passalacqua, M., Gaggero, D., Patrone, M., Pontremoli, S., and Melloni, E. (2002) Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced glycation end-products. Biochem. J. 363, 529-535
214. Sorci, G., Riuzzi, F., Agneletti, A. L., Marchetti, C., and Donato, R. (2004) S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J. Cell. Physiol. 199, 274-283
215. Yan, S. D., Stern, D., Kane, M. D., Kuo, Y. M., Lampert, H. C., and Roher, A. E. (1998) RAGE-Aβ interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 12, 167-173
216. Sousa, M. M., Yan, S. D., Stern, D., and Saraiva, M. J. (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κ-B (NF-κ-B) activation. Lab. Invest. 80, 1101-1110
217. Lue, L. F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., Stern, D. M., and Yan, S. D. (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171, 29-45
218. Carroll, L., Hannawi, S., Marwick, T., and Thomas, R. (2006) Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. Wien. Med. Wochenschr. 156, 42-52
219. Strickland, D. K., Kounnas, M. Z., and Argraves, W. S. (1995) LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J. 9, 890-898
220. Knauer, M. F., Kridel, S. J., Hawley, S. B., and Knauer, D. J. (1997) The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins. J. Biol. Chem. 272, 29039-29045
221. Godyna, S., Liau, G., Popa, I., Stefansson, S., and Argraves, W. S. (1995) Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J. Cell Biol. 129, 1403-1410
222. Bu, G., Geuze, H. J., Strous, G. J., and Schwartz, A. L. (1995) 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J. 14, 2269-2280
223. Deane, R., Wu, Z., Sagare, A., Davis, J., Du, Y. S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., Spijkers, P., Guo, H., Song, X., Lenting, P. J., Van Nostrand, W. E., and Zlokovic, B. V. (2004) LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43, 333-344
224. Hofer, F., Gruenberger, M., Kowalski, H., Machat, H., Huettinger, M., Kuechler, E., and Blaas, D. (1994) Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. U. S. A. 91, 1839-1842
225. Zerbinatti, C. V. and Bu, G. (2005) LRP and Alzheimer's disease. Rev. Neurosci. 16, 123-135
226. Kaczmarek, E., Lee, M. H., and McDonagh, J. (1993) Initial interaction between fibrin and tissue plasminogen activator (t-PA): the Gly-Pro-Arg-Pro binding site on fibrin(ogen) is important for t-PA activity. J. Biol. Chem. 268, 2474-2479
227. Westergaard, U. B., Andersen, M. H., Heegaard, C. W., Fedosov, S. N., and Petersen, T. E. (2003) Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur. J. Biochem. 270, 1850-1854
228. Ridker, P. M. (1994) Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events. J. Thromb. Thrombolysis 1, 35-40
229. Zahedi, K. (1997) Characterization of the binding of serum amyloid P to laminin. J. Biol. Chem. 272, 2143-2148
230. Du Clos, T. W. (1996) The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol. Biol. Rep. 23, 253-260
231. Pepys, M. B., Booth, S. E., Tennent, G. A., Butler, P. J., and Williams, D. G. (1994) Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin. Exp. Immunol. 97, 152-157
232. Liko, I., Mak, M., Klement, E., Hunyadi-Gulyas, E., Pazmany, T., Medzihradszky, K. F., and Urbanyi, Z. (2007) Evidence for an extended interacting surface between β-amyloid and serum amyloid P component. Neurosci. Lett. 412, 51-55
233. De Haas, C. J., van Leeuwen, E. M., van Bommel, T., Verhoef, J., van Kessel, K. P., and van Strijp, J. A. (2000) Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect. Immun. 68, 1753-1759
234. De Haas, C. J. (1999) New insights into the role of serum amyloid P component, a novel lipopolysaccharide-binding protein. FEMS Immunol. Med. Microbiol. 26, 197-202
235. Rostagno, A., Lashley, T., Ng, D., Meyerson, J., Braendgaard, H., Plant, G., Bojsen-Moller, M., Holton, J., Frangione, B., Revesz, T., and Ghiso, J. (2007) Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease. J. Neurol. Sci. 257, 88-96
236. Urbanyi, Z., Laszlo, L., Tomasi, T. B., Toth, E., Mekes, E., Sass, M., and Pazmany, T. (2003) Serum amyloid P component induces neuronal apoptosis and β-amyloid immunoreactivity. Brain Res. 988, 69-77
237. Li, X. A., Hatanaka, K., Ishibashi-Ueda, H., Yutani, C., and Yamamoto, A. (1995) Characterization of serum amyloid P component from human aortic atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15, 252-257
238. Tacnet-Delorme, P., Chevallier, S., and Arlaud, G. J. (2001) β-Amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for Aβ on the C1q globular regions. J. Immunol. 167, 6374-6381
239. Head, E., and Lott, I. T. (2004) Down syndrome and β-amyloid deposition. Curr. Opin. Neurol. 17, 95-100
240. Fonseca, M. I., Zhou, J., Botto, M., and Tenner, A. J. (2004) Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24, 6457-6465
241. Choi-Miura, N. H., and Oda, T. (1996) Relationship between multifunctional protein "clusterin" and Alzheimer disease. Neurobiol. Aging 17, 717-722
242. Partridge, S. R., Baker, M. S., Walker, M. J., and Wilson, M. R. (1996) Clusterin, a putative complement regulator, binds to the cell surface of Staphylococcus aureus clinical isolates. Infect. Immun. 64, 4324-4329
243. Kujiraoka, T., Hattori, H., Miwa, Y., Ishihara, M., Ueno, T., Ishii, J., Tsuji, M., Iwasaki, T., Sasaguri, Y., Fujioka, T., Saito, S., Tsushima, M., Maruyama, T., Miller, I. P., Miller, N. E., and Egashira, T. (2006) Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J. Atheroscler. Thromb. 13, 314-322
244. DeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A., Bales, K. R., Paul, S. M., Aronow, B. J., and Holtzman, D. M. (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99, 10843-10848
245. Trougakos, I. P., Gonos, E. S. (2002) Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell. Biol. 34, 1430-1448
246. Fowler, D. M., Koulov, A. V., Balch, W. E., and Kelly, J. W. (2007) Functional amyloid - from bacteria to humans. Trends Biochem. Sci. 32, 217-224
247. Harrison, R. S., Sharpe, P. C., Singh, Y., and Fairlie, D. P. (2007) Amyloid peptides and proteins in review. Rev. Physiol. Biochem. Pharmacol. 159, 1-77
248. Chiti, F., and Dobson, C. M. (2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366
249. Kelly, J. W., and Balch, W. E. (2003) Amyloid as a natural product. J. Cell Biol. 161, 461-462
250. Litvinovich, S. V., Brew, S. A., Aota, S., Akiyama, S. K., Haudenschild, C., and Ingham, K. C. (1998) Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. J. Mol. Biol. 280, 245-258
251. Kallijarvi, J., Haltia, M., and Baumann, M. H. (2001) Amphoterin includes a sequence motif which is homologous to the Alzheimer's β-amyloid peptide (Aβ), forms amyloid fibrils in vitro, and binds avidly to Aβ. Biochemistry 40, 10032-10037
252. Gebbink, M. F., Claessen, D., Bouma, B., Dijkhuizen, L., and Wosten, H. A. (2005) Amyloids - a functional coat for microorganisms. Nat. Rev. Microbiol. 3, 333-341
253. Wickner, R. B., Edskes, H. K., Shewmaker, F., and Nakayashiki, T. (2007) Prions of fungi: inherited structures and biological roles. Nat. Rev. Microbiol. 5, 611-618
254. Berson, J. F., Theos, A. C., Harper, D. C., Tenza, D., Raposo, G., and Marks, M. S. (2003) Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J. Cell Biol. 161, 521-533
255. Kenney, J. M., Knight, D., Wise, M. J., and Vollrath, F. (2002) Amyloidogenic nature of spider silk. Eur. J. Biochem. 269, 4159-4163
256. Chapman, M. R., Robinson, L. S., Pinkner, J. S., Roth, R., Heuser, J., Hammar, M., Normark, S., and Hultgren, S. J. (2002) Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295, 851-855
257. Butko, P., Buford, J. P., Goodwin, J. S., Stroud, P. A., McCormick, C. L., and Cannon, G. C. (2001) Spectroscopic evidence for amyloid-like interfacial self-assembly of hydrophobin Sc3. Biochem. Biophys. Res. Commun. 280, 212-215
258. Vieira, M. N., Figueroa-Villar, J. D., Meirelles, M. N., Ferreira, S. T., and De Felice, F. G. (2006) Small molecule inhibitors of lysozyme amyloid aggregation. Cell Biochem. Biophys. 44, 549-553
259. Morais-de-Sa, E., Neto-Silva, R. M., Pereira, P. J., Saraiva, M. J., and Damas, A. M. (2006) The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallogr. Allogr. D Biol. Crystallogr. 62, 512-519
260. Necula, M., Kayed, R., Milton, S., and Glabe, C. G. (2007) Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311-10324
261. Kisilevsky, R., Ancsin, J. B., Szarek, W. A., and Petanceska, S. (2007) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14, 21-32
262. Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., and Kelly, J. W. (1998) Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 95, 12956-12960
263. White, J. T., and Kelly, J. W. (2001) Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl. Acad. Sci. U. S. A. 98, 13019-13024
264. Solomon, B., and Frenkel, D. (2000) Vaccination for the prevention and treatment of Alzheimer's disease. Drugs Today (Barc.) 36, 655-663
265. Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L., Trojanowski, J. Q., Abel, T., and Lee, V. M. (2006) Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. 281, 4292-4299
266. Broytman, O., and Malter, J. S. (2004) Anti-Aβ: the good, the bad, and the unforeseen. J. Neurosci. Res. 75, 301-306
267. Goni, F., Knudsen, E., Schreiber, F., Scholtzova, H., Pankiewicz, J., Carp, R., Meeker, H. C., Rubenstein, R., Brown, D. R., Sy, M. S., Chabalgoity, J. A., Sigurdsson, E. M., and Wisniewski, T. (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413-421
268. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177
269. Sigurdsson, E. M., Brown, D. R., Daniels, M., Kascsak, R. J., Kascsak, R., Carp, R., Meeker, H. C., Frangione, B., and Wisniewski, T. (2002) Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17
270. Imbimbo, B. P. (2002) Toxicity of β-amyloid vaccination in patients with Alzheimer's disease. Ann. Neurol. 51, 794
271. O'Nuallain, B., and Wetzel, R. (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U. S. A. 99, 1485-1490
272. Solomon, B. (2007) Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 16, 819-828
273. Miyata, T., Hori, O., Zhang, J., Yan, S. D., Ferran, L., Iida, Y., and Schmidt, A. M. (1996) The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-β2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. J. Clin. Invest. 98, 1088-1094
274. Geroldi, D., Falcone, C., and Emanuele, E. (2006) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13, 1971-1978
275. Yan, S. F., Naka, Y., Hudson, B. I., Herold, K., Yan, S. D., Ramasamy, R., and Schmidt, A. M. (2006) The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Curr. Atheroscler. Rep. 8, 232-239
276. Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., and Kindy, M. (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643-651
277. Cacquevel, M., Launay, S., Castel, H., Benchenane, K., Cheenne, S., Buee, L., Moons, L., Delacourte, A., Carmeliet, P., and Vivien, D. (2007) Ageing and amyloid-β peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol. Dis. 27, 164-173
278. Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., Scheff, S., McGillis, J. P., Rydel, R. E., and Estus, S. (2000) The plasmin system is induced by and degrades amyloid-β aggregates. J. Neurosci. 20, 3937-3946
279. Medina, M. G., Ledesma, M. D., Dominguez, J. E., Medina, M., Zafra, D., Alameda, F., Dotti, C. G., and Navarro, P. (2005) Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J. 24, 1706-1716
280. Tucker, H. M., Kihiko-Ehmann, M., Wright, S., Rydel, R. E., and Estus, S. (2000) Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition. J. Neurochem. 75, 2172-2177
281. East, E., Baker, D., Pryce, G., Lijnen, H. R., Cuzner, M. L., and Gveric, D. (2005) A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am. J. Pathol. 167, 545-554